Anders Helander1, Asgeir Husa, Jan-Olof Jeppsson. 1. Department of Clinical Neuroscience, Karolinska Institutet and Hospital, SE-171 76 Stockholm, Sweden. anders.helander@cns.ki.se
Abstract
BACKGROUND: There is need for a reference method for transferrin glycoforms in serum to which routine immunologic methods for the alcohol marker carbohydrate-deficient transferrin (CDT) can be traceable. We describe an improved HPLC method for transferrin glycoforms. METHODS: Transferrin was iron-saturated by mixing the serum with ferric nitrilotriacetic acid, and lipoproteins were precipitated with dextran sulfate and calcium chloride. Separation of glycoforms was performed on a SOURCE 15Q anion-exchange column using salt gradient elution. Quantification relied on selective absorbance of the iron-transferrin complex at 470 nm. The relative amount of each glycoform was calculated as a percentage of the area under the curve, using baseline integration. RESULTS: The HPLC system provided reproducible separation and quantification of the asialo-, monosialo-, disialo-, trisialo-, tetrasialo-, pentasialo-, and hexasialotransferrin glycoforms. Most importantly, disialo- and trisialotransferrin were almost baseline separated. The intra- and interassay CV for disialotransferrin were <5%. Serum and the pretreated samples were stable for at least 2 days at 22 or 4 degrees C. Sera from 132 healthy controls contained [mean (SD)] 1.16 (0.25)% disialotransferrin, 4.77 (1.36)% trisialotransferrin, 80.18 (2.01)% tetrasialotransferrin, and 13.88 (1.69)% pentasialo- + hexasialotransferrin. In some cases of a high (>6%) trisialotransferrin, monosialotransferrin was detected at <0.25%. Asialotransferrin was not detected in control sera, but was detected in 57% of chronic heavy drinkers and in 62% of sera with >/=2% disialotransferrin. CONCLUSIONS: The HPLC method fulfills the requirements of a preliminary reference method for CDT and should work for any combination of serum transferrin glycoforms. This method could also be useful for confirming positive CDT results by immunoassays in medico-legal cases.
BACKGROUND: There is need for a reference method for transferrin glycoforms in serum to which routine immunologic methods for the alcohol marker carbohydrate-deficient transferrin (CDT) can be traceable. We describe an improved HPLC method for transferrin glycoforms. METHODS:Transferrin was iron-saturated by mixing the serum with ferric nitrilotriacetic acid, and lipoproteins were precipitated with dextran sulfate and calcium chloride. Separation of glycoforms was performed on a SOURCE 15Q anion-exchange column using salt gradient elution. Quantification relied on selective absorbance of the iron-transferrin complex at 470 nm. The relative amount of each glycoform was calculated as a percentage of the area under the curve, using baseline integration. RESULTS: The HPLC system provided reproducible separation and quantification of the asialo-, monosialo-, disialo-, trisialo-, tetrasialo-, pentasialo-, and hexasialotransferrin glycoforms. Most importantly, disialo- and trisialotransferrin were almost baseline separated. The intra- and interassay CV for disialotransferrin were <5%. Serum and the pretreated samples were stable for at least 2 days at 22 or 4 degrees C. Sera from 132 healthy controls contained [mean (SD)] 1.16 (0.25)% disialotransferrin, 4.77 (1.36)% trisialotransferrin, 80.18 (2.01)% tetrasialotransferrin, and 13.88 (1.69)% pentasialo- + hexasialotransferrin. In some cases of a high (>6%) trisialotransferrin, monosialotransferrin was detected at <0.25%. Asialotransferrin was not detected in control sera, but was detected in 57% of chronic heavy drinkers and in 62% of sera with >/=2% disialotransferrin. CONCLUSIONS: The HPLC method fulfills the requirements of a preliminary reference method for CDT and should work for any combination of serum transferrin glycoforms. This method could also be useful for confirming positive CDT results by immunoassays in medico-legal cases.
Authors: Scott H Stewart; David G Koch; Douglas M Burgess; Ira R Willner; Adrian Reuben Journal: Alcohol Clin Exp Res Date: 2012-06-22 Impact factor: 3.455
Authors: M B Bistué Millón; M A Delgado; N B Azar; N Guelbert; L Sturiale; D Garozzo; G Matthijs; J Jaeken; Raquel Dodelson de Kremer; C G Asteggiano Journal: JIMD Rep Date: 2011-06-22
Authors: Scott H Stewart; David G Koch; Ira R Willner; Raymond F Anton; Adrian Reuben Journal: Alcohol Clin Exp Res Date: 2014-05-21 Impact factor: 3.455
Authors: María E de la Morena-Barrio; María J Ballesta-Martínez; Raquel López-Gálvez; Ana I Antón; Vanessa López-González; Laia Martínez-Ribot; José Padilla; Antonia Miñano; Oscar García-Algar; Miguel Del Campo; Javier Corral; Encarna Guillén-Navarro; Vicente Vicente Journal: Pediatr Res Date: 2017-09-20 Impact factor: 3.756
Authors: Ludmila N Bakhireva; Sandra Cano; William F Rayburn; Renate D Savich; Lawrence Leeman; Raymond F Anton; Daniel D Savage Journal: Alcohol Alcohol Date: 2012-08-08 Impact factor: 2.826
Authors: Raymond F Anton; Patricia Latham; Konstantin Voronin; Sarah Book; Michaela Hoffman; James Prisciandaro; Emily Bristol Journal: JAMA Intern Med Date: 2020-05-01 Impact factor: 21.873